Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) [0.03%]
血液系统肿瘤患者两剂BNT162b2新冠疫苗接种后体液及细胞免疫应答的单中心前瞻性观察研究(NCT05074706)
Elisa Bossi,Andrea Aroldi,Lorenza Maria Borin et al.
Elisa Bossi et al.
Hematological patients at higher risk of severe COVID-19 were excluded from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine trials. In this single-center observational prospective study (NCT05074706), we evaluate im...
Increased prescription rate of anti-infective agents after diagnosis of myelodysplastic syndromes [0.03%]
诊断骨髓增生异常综合征后抗感染药物处方率增加
Johanne Rozema,Mels Hoogendoorn,Iris Potma et al.
Johanne Rozema et al.
The a priori risk for infections in patients with myelodysplastic syndromes (MDS) is unknown. This study examines prescription rates of anti-infective agents in MDS patients before and after diagnosis, in both in- and outpatient settings, t...
Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy [0.03%]
异质性的遗传和非遗传机制会影响氟达拉滨单药治疗的疗效和耐药性
Vasiliki Symeonidou,Marlen Metzner,Batchimeg Usukhbayar et al.
Vasiliki Symeonidou et al.
Acute myeloid leukaemia is prevalent in older patients that are often ineligible for intensive chemotherapy and treatment options remain limited with azacitidine being at the forefront. Azacitidine has been used in the clinic for decades, h...
18F-fluorodeoxyglucose-positron emission tomography/computed tomography delineates involved sites in the cervical spine in Langerhans cell histiocytosis [0.03%]
18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描可显示朗格汉斯细胞组织细胞增生症颈椎受累部位
Shinsaku Imashuku,Hiroko Tsunemine,Chihiro Shimazaki
Shinsaku Imashuku
siRNA against CD40 delivered via a fungal recognition receptor ameliorates murine acute graft-versus-host disease [0.03%]
靶向CD40的小干扰RNA通过真菌识别受体介导改善小鼠急性移植物抗宿主病
Beate Heissig,Yousef Salama,Masatoshi Tateno et al.
Beate Heissig et al.
Acute graft-versus-host disease (aGvHD) remains a major threat to a successful outcome after allogeneic hematopoietic stem cell transplantation (HSCT). Although antibody-based targeting of the CD40/CD40 ligand costimulatory pathway can prev...
Vivian K P Yeung
Vivian K P Yeung
Long-term efficacy and safety of programmed death-1 (PD-1) antibody alone in relapsed/refractory human immunodeficiency virus-associated Hodgkin lymphoma [0.03%]
复发/难治性人类免疫缺陷病毒所致霍奇金淋巴瘤患者接受抗程序死亡-1(PD-1)抗体单药治疗的长期疗效及安全性评估
Chaoyu Wang,Fanlin Zhou,Lingqian Zhang et al.
Chaoyu Wang et al.
We report a young patient initially diagnosed with human immunodeficiency virus (HIV)-associated Hodgkin lymphoma (HL), and received six cycles of ABVD chemotherapy regimens and involvement field irradiation therapy. However, the disease pr...
CB-103: A novel CSL-NICD inhibitor for the treatment of NOTCH-driven T-cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T-ALL [0.03%]
CB-103：一种新型的CSL-NICD抑制剂可治疗NOTCH驱动的T细胞急性淋巴细胞白血病：一例复发/难治性T-ALL患者完全临床反应的病例报告
Michael Medinger,Till Junker,Dominik Heim et al.
Michael Medinger et al.
Relapsed T cell acute lymphoblastic leukaemia (T-ALL) has a very poor prognosis. A 24-year-old patient with relapsed high-risk T-ALL (PTEN gene deletion; NOTCH1 mutation), was treated with the NOTCH inhibitor CB-103. Within 1 week of starti...
Case Reports
EJHaem. 2022 Jun 16;3(3):1009-1012. DOI:10.1002/jha2.510 2022
A multicenter, real-world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus [0.03%]
HIV阳性和阴性患者一级中枢神经系统淋巴瘤的多中心真实世界分析
Christopher Dittus,Natalie Grover,Tarsheen Sethi et al.
Christopher Dittus et al.
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma [0.03%]
药理学筛选确定了BET抑制剂的活性组合并将LRRK2鉴定为淋巴瘤中的新型潜在靶点
Filippo Spriano,Giulio Sartori,Chiara Tarantelli et al.
Filippo Spriano et al.
Inhibitors of the Bromo- and Extra-Terminal domain (BET) family proteins have strong preclinical antitumor activity in multiple tumor models, including lymphomas. Limited single-agent activity has been reported in the clinical setting. Here...